Michael J Fox Foundation for Parkinson's Research, 90 Broad Street, New York, NY 07030, USA.
Biomark Med. 2010 Oct;4(5):723-9. doi: 10.2217/bmm.10.89.
Therapeutic development in Parkinson's disease is hampered by the paucity of well-validated biomarkers that can assist with diagnosis and/or tracking the progression of the disease. Since its inception, the Michael J Fox Foundation for Parkinson's Research has invested heavily in biomarker research and continues to prioritize discovery and development efforts. This article summarizes the history and evolution of the Michael J Fox Foundation's role in supporting biomarker research and lays out the current challenges in successfully developing markers that can be used to test therapies, while also providing a vision of future funding efforts in Parkinson's disease biomarkers.
帕金森病的治疗开发受到缺乏经过充分验证的生物标志物的阻碍，这些生物标志物可以帮助诊断和/或跟踪疾病的进展。自成立以来，迈克尔·J·福克斯基金会（Michael J Fox Foundation for Parkinson's Research）一直大力投资于生物标志物研究，并继续优先开展发现和开发工作。本文总结了迈克尔·J·福克斯基金会支持生物标志物研究的历史和演变，并概述了当前成功开发可用于测试治疗方法的标志物所面临的挑战，同时还展望了帕金森病生物标志物的未来资助工作。
